Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a
clinical stage biopharmaceutical company and a leading developer of
oncology compounds directed to cancer stem cell targets, today
announced that the Company's CEO, Ivan Bergstein M.D. has been
invited to present at the New Frontiers in Cancer Drug Development
conference which is part of IBC's Drug Discovery and Development
Week in Boston, MA. Dr. Bergstein's presentation, entitled
"Developing Drug Candidates Directed to Cancer Stem Cell Targets:
Preclinical and Clinical Update" is scheduled for 9:50AM on
Wednesday August 5th at the World Trade Center/Seaport Hotel in
Boston. Dr. Bergstein has also been invited to participate in a
panel discussion following the presentations.
Cancer stem cell targeted therapeutics have emerged as the next
frontier in the fight against cancer. As such, this field is
significantly influencing current decision making with respect to
oncology drug development. With this in mind, Dr. Bergstein's
presentation will cover novel pre-clinical and clinical development
paradigms, including human trial design, of drug candidates that
target cancer stem cells. The talk will also feature Stemline's
latest clinical data, as well as results from its pre-clinical
pipeline and drug discovery platforms.
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biotechnology
company developing novel oncology compounds directed to cancer stem
cell targets. Stemline's lead compound, SL-401, targets the
interleukin-3 receptor present on multiple hematological cancers
including leukemia blasts and leukemia cancer stem cells. SL-401
has demonstrated single agent anti-tumor activity at tolerable
doses in a multi-center Phase I human clinical trial. Stemline is
also developing a portfolio of biological and small molecule
compounds directed at multiple high value cancer stem cell targets
of a variety of hematological and solid cancers. Stemline has built
a robust discovery platform called "StemScreen " which the Company
has utilized to identify multiple compounds that target and impair
cancer stem cells. For more information, please visit the Company's
website at www.stemline.com.
Stemline Contact: Tom Cirrito, PhD, Director of Operations,
Therapeutics, Inc. Tel: 212-531-5976; Email: firstname.lastname@example.org
Source: Stemline Therapeutics, Inc.
CONTACT: Tom Cirrito, PhD, Director of Operations of
Therapeutics, Inc. +1-212-531-5976, email@example.com
Web Site: http://www.stemline.com
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: July 2009